Motivation: Many methods of identifying differential expression in genes depend on testing the null hypotheses of exactly equal means or distributions of expression levels for each
INTRODUCTION
Microarray technology enables the simultaneous measurement of the expression levels of genes throughout the genome. The use of microarrays to discover genes, which are differentially expressed between two or more groups of patients has many biomedical applications, including the identification of disease biomarkers that can potentially be used to understand better and diagnose diseases. While reliable statistical methods for discovering genes that are differentially expressed have been developed, the degree to which each gene is differentially expressed has been largely neglected from a statistical viewpoint. This paper addresses this deficiency within the statistical framework of multiple comparison procedures (MCPs).
MCPs, including p-value correction (Westfall and Young, 1993) , false discovery rate control (Benjamini and Hochberg, 1995; Storey, 2002a; Efron and Tibshirani, 2002; Fernando et al., 2003) , decision-theoretic optimization (Storey, 2003; Müller et al., 2002 , http://www.ceremade.dauphine.fr/~xian/ publications.html or http://www.ceremade.dauphine.fr/ CMD_2002.php; Bickel, 2003b, www. arxiv.org and www.mathpreprints.com) and achievement of a posterior probability (Efron et al., 2001; Genovese and Wasserman, 2002) have been applied to microarray data to achieve the goal of discovering which genes are differentially expressed. This goal is distinct from that of classifying patients based on gene expression profiles, for which discrimination methods are better suited (e.g. Dudoit et al., 2002) . It also differs from the goal of grouping genes or microarrays together based on similar expression patterns, as in cluster analysis (e.g. Bickel, 2003a and references therein). The research herein builds on MCPs, with the first goal in mind for the analysis of data. However, the use of receiver operating characteristics in MCPs makes the discovered genes potentially useful as biomarkers for the classification goal. The use of such genes may improve the classification accuracy of discrimination methods.
of classification accuracy that includes all possible decision thresholds, making the AUC particularly important for clinical settings. If X is a random variable representing the expression levels of a gene for one group of patients and Y is that for another group, then the AUC for the two groups is equal to the probability that a randomly selected patient from one group will have a greater expression value than a random patient from the other group: AUC = Pr(Y > X) (Green and Swets, 1966) . This means that, given an abnormal individual and a normal individual, the AUC is the probability that the gene expression levels can correctly identify them, as Hanley and McNeil (1982) explained in terms of radiology. Thus, AUCs around one-half indicate a complete lack of discriminating power (50% chance of correct identification), whereas AUC = 1 indicates perfect discrimination (100% chance of correct identification; 100% sensitivity and specificity). Another advantage of the AUC is that it is easily estimated by the familiar Wilcoxon rank-sum statistic (Hanley and McNeil, 1982) , as Pepe et al. (2003) noted in the context of microarray data analysis. Since such AUC estimation is non-parametric, it does not require assumptions about the family of distributions of the levels of gene expression; even assumptions about equal shapes of the distribution are not needed. Although t-statistics do not require such assumptions when permutations are used to generate the null distribution, the permutations can be very costly in terms of computation time. Thus, this paper focuses on the AUC as the level of differential gene expression, as estimated by the rank-sum statistic (Efron and Tibshirani, 2002) , but the new methods apply to other measures of expression differences as well. Alternatives are discussed at the end of the paper.
NEW METHODS
This section addresses two questions related to the degrees of differential expression:
(1) Which genes have not just statistical significance, but also biologically or clinically relevant differential expression? Most determinations of statistical significance, including commercial software packages that rely on MCPs, consider a gene differentially expressed if it has any difference in expression, even scientifically negligible differences. Such approaches are misleading since a sufficiently large sample size could always find statistical significance for every gene. For example, the population ('true') AUC of two groups may be approximately 0.501, which is negligible from a clinical point of view since classification accuracy would only differ from chance by 0.1%, and yet such a difference would be detected if there are enough microarrays. This is not just a problem for large sample sizes: the following application to two cancer datasets shows that the detection of differential expression depends on the degree of difference that is considered biologically relevant. 
In false discovery rate terminology, a rejection of the ith null hypothesis (R i = 1) is called a discovery of differential expression in the ith gene, whereas the corresponding failure to reject (R i = 0) is called a nondiscovery. A true discovery is the discovery of differential expression in a gene that is relevantly differentially expressed (H i = R i = 1), whereas a false discovery is the discovery of differential expression in a gene that is not really relevantly differentially expressed (H i = 0, R i = 1). True and false nondiscoveries are similarly defined. Most researchers select t 0 = t min out of convenience, often unknowingly, but that is inadequate since such a selection has no regard for what would be considered a biologically or clinically relevant level of differential expression. It effectively tests whether there is any difference in expression at all, even when detected differences would be scientifically negligible. Furthermore, given t 0 = t min and a large enough sample size, all genes would be discovered to be expressed differentially because ∀ i t i > t min for any real biological dataset, even though ∃ i t i = t min would be possible for artificial theoretical models and their simulated datasets. The selection t 0 = t min corresponds to defining 'differential expression' as any expression difference, no matter how small. The results of the statistical analysis will have more meaning when genes are only defined to be expressed differentially if the expression difference must exceed some threshold level t 0 that satisfies t 0 > t min . By the suggested definition of relevant differential expression, the ith gene is only relevantly differentially expressed if t i > t 0 > t min , instead of the less stringent criterion t i > t min . The proposed null hypotheses and definitions of differential expression are compatible with any MCP criterion for determining the value of τ . For example, the use of values of t 0 that are greater than t min can be applied to p-value correction (control of a familywise error rate), control of a false discovery rate, satisfaction of a minimum posterior probability of differential expression or decision-theoretic optimization. For illustrative purposes, a variant of false discovery rate control is used herein since such control is much more powerful than p-value adjustment and since it is more widely used than the decision-theoretic and probability-threshold approaches.
Since H i is a random variable in Bayesian approaches, t i is also a random variable for fixed t 0 . (Bayesian approaches treat estimated parameters as random variables. The ith test statistic, t i , is also a random variable, and has an observation denoted by T i for a particular sample.) Storey (2003) showed that Pr(H i = 0|t i ≥ τ ) = ∇(τ ), where ∇(τ ) is the proportion of false positives (PFP; Fernando et al., 2003) , the ratio of the expected number of false rejections to the expected total number of rejections for the rejection region given by {t: t ≥ τ }. (The rejection region is the space that contains only the test statistics corresponding to genes considered differentially expressed.) It follows that
Although ∇(τ ) has several advantages over conventional false discovery rates (Fernando et al., 2003) , it cannot be controlled in the sense that Benjamini and Hochberg (1995) control the false discovery rate since ∇(τ ) is undefined when ∀ i∈{1,2, ... , m} Pr(t i ≥ τ ) = 0, which can occur when all null hypotheses are true. This can be addressed by introducing (τ ), defined to be equal to ∇(τ ) if the expected number of rejections is positive, and to be equal to 0 otherwise. [Since (τ ) has additional advantages in decision-theoretic analyses (D.R. Bickel, submitted for publication), it is called the decisive false discovery rate (dFDR).] (τ ), when considered as a function of t 0 , is equal to a CDF of t i for t i ≥ τ even when that CDF is defined, and is equal to 0 when that CDF is not applicable. It follows that t 0 is the (τ ) quantile of {t i : t i ≥ τ }, i.e. of differential expression parameters that correspond to test statistics in the rejection region, when such a quantile is meaningful. This observation can provide solutions to the following problem. Given t 0 and goal , a fixed value of (τ ), find the value of τ that defines the rejection region. For example, selecting t 0 = t min and goal = 5% leads to standard control of the dFDR in the sense of rejecting as many null hypotheses as possible with the constraint that the dFDR does not exceed 5%. On the other hand, selecting goal = 50% gives the rejection region for which some given t 0 is the median of t i . Ifˆ (τ ) is a conservative estimate of (τ ), then finding the smallest value of τ for whichˆ (τ ) ≤ goal finds a conservative rejection region in the sense that the expected goal quantile of the differences in expression is at least t 0 . [If no null hypotheses are rejected,ˆ (τ ) = 0, so there is always some τ for whichˆ (τ ) ≤ goal .] This effect of conservative estimation was observed in the first simulation study described below. Storey (2002a) proved that estimators of the form of those of Efron et al. (2001) , Storey (2003) and Efron and Tibshirani (2002) are conservative under reasonable assumptions, so the quantile method of this paper applies to such estimators. They satisfy∇
whereπ 0 ,F 0 (τ ) andF (τ ) are estimators of the proportion of null hypotheses that are true (the proportion of genes that are not differentially expressed), of the distribution of null test statistics, and of the distribution of all test statistics, respectively.∇(τ ) can be used to estimate the false discovery rate of Benjamini and Hochberg (1995) or, with modification, the positive false discovery rate (Storey, 2003) under the independence or weak dependence of test statistics (Storey, 2003) . Without assumptions about the dependence of test statistics, ∇(τ ) also estimates the PFP (Fernando et al., 2003) , which is equivalent for random H i to the Bayesian false discovery rate (Efron and Tibshirani, 2002) . The definition of (τ ) suggests its estimation bŷ
F is an empirical distribution of the test statistics,F 0 can be an empirical distribution of test statistics after permutation, and there are various ways to computeπ 0 . Here, we use the conservative selectionπ 0 ≡ 1 for simplicity, following Benjamini and Hochberg (1995) .
Equations (1) and (2) are appropriate when the test statistics are defined such that a sufficiently high test statistic implies a discovery, the rejection of a null hypothesis that a gene is not differentially expressed, e.g. T i could be the absolute value of a t-statistic for a two-sided test. (The notation can be slightly modified for more general rejection regions, e.g. for asymmetric regions.) If p-values P 1 , P 2 , . . . , P m are used in the place of test statistics, so that R i = 1 if P 1 ≤ or R i = 0 if P i > for some positive threshold , Equations (1) and (2) becomê
andˆ
since the distribution of p-values is uniform under the null hypothesis (Storey, 2002a; Genovese and Wasserman, 2002) . In this case,F ( ) is the proportion of observed p-values that are less than or equal to . The dFDR is controlled by rejecting as many null hypotheses as possible, subject to the constraintˆ (τ ) ≤ goal orˆ ≤ goal . Since the AUC is important in clinical settings, and since the Wilcoxon rank-sum statistic estimates the AUC, the p-values of the two-sided Wilcoxon rank-sum test were used as P 1 , P 2 , . . . , P m to computeˆ . Then (τ ) was defined to satisfyˆ (τ ) =ˆ for the purpose of the above quantile interpretation. (Wilcoxon statistics also have the advantages that statistical tests can be performed without distributional assumptions, and that they are invariant to monotonic transforms of the data such as the log transform. Furthermore, a normal approximation can be used with Wilcoxon statistics to speed calculations by obviating permutations.)
Method 2: correcting the bias in estimates of expression differences
Let ρ i be the rank of T i , the observed test statistic of the ith gene, such that T i is the ρ i th smallest observed test statistic among all m genes. Similarly, let r i be the rank of t i . The problem to be corrected is that, for a large rank r,
What is desired is an estimatort i that satisfies E{t i |r i = r} ≈ E{t i |{r i = r}, wherer i denotes the rank oft i . If ∀ i r i = i, then E{t i |r i = r} = E{t r }, so that t i should satisfy E{t i |r i = r} ≈ E{t r }. (T i is an observation of the variable t i , but for simplicity of notation, other observations are not distinguished from their random variables.) Since the bias, E{t i |ρ i = r} − E{t i |r i = r}, is due to using the same data to rank the genes that is used to estimate the effect sizes (expression differences), it can be reduced by randomly designating half of the microarrays as 'microarrays for ranks' to determine the ranks, and the other half as 'microarrays for expression' to estimate the expression differences. This is accomplished by estimating the expression difference of the gene with the rth smallest expression difference in {T i } m i=1 by the mean expression difference of the microarrays for expression for the genes whose ranks among the microarrays for ranks are equal to r. If the new expression difference is greater than the original one, the original one is used in its place since a positive bias is being corrected. This procedure may be implemented by the first 12 steps of the algorithm of Appendix A (online supplement). In mathematical terms, the expression difference of the ith gene is
where J is the number of microarrays are chosen without replacement for ranks or for expression, and where, for the j th iteration, t * * * j ,(ρi) is the test statistic of the microarrays for expression for the gene with the ρ i th lowest test statistic of the microarrays for ranks. It can be seen that the ranks and the expression differences are determined from different microarrays since the ranks of
can be used to make inferences about the expression differences of genes with certain ranks given by
, the investigator will have a better idea of what the expression values are of the genes that were identified as differentially expressed by controlling the false discovery rate at the 5% level.
However, this method has the problem that a gene thought to be more differentially expressed than another can have a lower estimated expression difference, i.e. ρ i ≤ ρ j does not imply thatt i ≤t j . That can be solved by enforcing monotonicity as in step-down methods of controlling a family-wise Type I error rate (Westfall and Young, 1993) , using a bias-corrected estimatort i that satisfies 
RESULTS

Simulation
Determining which simulated genes have relevant differential expression How closely t 0 matches the actual goal quantiles for actual rejection regions was determined by simulation. Each simulated set of microarrays consists of two samples of 20 microarrays each, with 5000 genes per microarray (m = 5000). For the first sample, called the control sample, each expression value is drawn from N(0, 1), where N(µ, σ 2 ) is the normal distribution with mean µ and Fig. 1 . µ i,treatment as a function of i. As with real expression data, even the irrelevant, negligible expression differences are not exactly equal to zero, though they appear to be zero for low i.
standard deviation σ . For the second sample, called the treatment sample, each expression value is drawn from N(µ i , 1), where i, the gene index, satisfies i ∈ {1, 2, 3, . . . , 5000} and µ i,treatment = 5(i/5000) 8 . As with real expression data, even the irrelevant, negligible expression differences are not exactly equal to zero, though µ i,treatment − µ i,control ≈ 0 for i 2000 (Fig. 1) . The probability that, for the gene with index i, a randomly selected observation in the treatment sample is greater than one in the control sample is equal to the AUC for that gene, as noted under 'Significance and Background':
A numerical integration shows that small differences in the mean expression level of a gene correspond to values of AUC near 0.5, making them clinically irrelevant, whereas large differences (µ i,treatment − 0 4) correspond to values of AUC approaching 1, as seen in Figure 2 . The best possible AUC is taken to be the expression difference of interest for gene i:
This equation is used, instead of simply setting t i to Pr(X i,treatment > X i,control ), in order to ensure that the analysis would also apply to the more general case in which the treatment causes genes to tend to be less expressed than in the control group. In other words, the absolute value enables two-sided tests of the AUC. In the case of the simulated data, the equation reduces to t i = Pr(X i,treatment > X i,control ). Then, since W i , the Wilcoxon rank-sum statistic for the ith gene, is an estimator of the AUC, an estimator of t i is
For W i to estimate the AUC, it must be normalized to lie between 0 and 1, as follows. For all possible treatmentcontrol comparisons of the ith gene, W i is the sum of the number of comparisons for which the expression value of the treatment group is greater than that of the control group and half the number of comparisons for which the expression value of the treatment group is equal to that of the control group, divided by the total number of comparisons. In other words,
where x i,j ,treatment is the observed expression value of the ith gene of the j th treatment microarray, and x i,j ,control is the observed expression value of the ith gene of the j th control microarray.
The simulations quantify how close the goal quantile of the expression differences of the genes with test statistics in the rejection region is to t 0 , the desired quantile. This was accomplished by using the known values of t i and finding the value of for whichˆ ≤ goal andˆ ≈ goal . For example, the settings goal = 50% and t 0 = 0.60 were used to find the value of τ for which the median value of the t i s with p-values in the rejection region is at least 0.60. (An AUC of 0.60 means that 60% of the time, a random observation from the treatment group will be greater than a random observation from the control group for a given gene.) Likewise, setting goal = 5% and t 0 = 0.60 determined which genes to consider differentially expressed such that the 5th percentile of the t i s with p-values in the rejection region is at least 0.60. The results for the simulated dataset are displayed in Table 1 , which gives the simulation quantiles of genes in the rejection region for goal = 5% (5th percentile) and goal = 50% (50th percentile or median). For real data, the true quantiles, those of {t i : T i ≥ τ }, are unknown, but Table 1 (Storey, 2002a) . The sample quantile is a good upper bound because the observed test statistics, {T i : T i ≥ τ }, have an upward bias due to the multiple comparisons problem: they were chosen because they are high enough to be in the rejection region. Nonetheless, lower and upper bounds on the quantiles do not estimate the degree to which each individual gene is differentially expressed.
Estimating the expression differences of the simulated genes
The estimatort i was tested by applying it to the simulated dataset of Table 1 with J = 50. The AUC bias is plotted as a function of the true AUC in Figure 3 . The bias for each of 5000 genes is estimated as the estimate of expression difference minus the true expression difference t i , as a function of t i . (Here, expression differences are AUCs.) The top curve is the estimated bias of t i , and the circles are the estimated biases of t i , for i ∈ {1, 2, . . . , 5000}. As expected, the bias oft i is lower than that of t i . For many values of the AUC, the negative bias of t i is greater than the positive bias of t i , but negative biases are less of a problem since they are conservative. (A negative bias means that the estimate is probably less than the true AUC.)
APPLICATIONS
Applications of the new methods to two cancer datasets and to a case of no differential expression are described in the online supplement. They illustrate the methods and indicate how much the methods can improve data analysis.
DISCUSSION
While either of the two methods proposed could be applied without the other, they naturally go together since both are concerned with effect sizes (expression differences), since both rely on a set of test statistics {t i } m i=1 , and since an investigator interested in the results of one method would often be interested in the results of the other: the first method tells the investigator which genes can be considered differentially expressed without saying anything about the levels of differential expression, and the second method yields estimates of expression differences without saying which genes have differential expression between two larger populations represented by the data at hand.
Investigators can choose statistics and parameters to tailor the methods to their specific goals in examining the data. These are application-specific decisions that cannot be made on the basis of statistics alone. The definition of expression difference as the AUC (6) and the choice of the Wilcoxon statistics (7) as estimators have many advantages, especially for clinical settings, as mentioned above. Since the AUC is the area under a plot of the sensitivity versus 1 minus the specificity, a biomedical researcher can choose t 0 on the basis of the minimum sensitivity that is clinically acceptable at each specificity. Alternately, to avoid such plots, t 0 may be chosen as the lowest clinically useful probability of correctly classifying two individuals, with one individual randomly selected from each of two groups. However, a definition of the expression difference that is a function of a fold change, with an appropriate estimator similar to a t-statistic, may be better for some studies. For example, an investigator may consider average fold changes of at least 1.5 to be biologically relevant, in which case t 0 = 1.5 for an appropriately defined t i . (This differs from the statistically unsound procedures that consider genes differentially expressed that have estimates of fold changes of at least a given threshold.)
While it may be helpful for comparison purposes to make the conventional choices t 0 = t min and goal = 5%, the choice t 0 = t min is too low for a thorough study of biological data since it would imply that all genes are differentially expressed and would be discovered as such, given a large enough sample size. The exact choices of t 0 and goal may not always be suggested by the biology, in which case investigators can benefit from seeing results for different choices presented as in Tables 2 and 3 (Supplementary information) . Alternately, investigators may decide on values of t 0 and goal on the basis of the bias-corrected estimates {t i } m i=1 . Some of the choices available to investigators are presented in Table 4 of Appendix B of the online supplement.
